Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

Yes, Repatha is still available as a medication used to help lower “bad” LDL cholesterol and reduce the risk of serious heart problems. However, while the medication itself is still available, the way ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

Following a price cut for its Repatha SureClick auto-injector in October, Amgen Inc. (AMGN) announced on Monday it is slashing the price of all Repatha devices by 60% to $5,850 per year. Repatha, one ...